RQM+ announced on August 28 its acquisition of CRO Kottmann for an undisclosed price. According to data captured in the LevinPro HC database, this transaction marks the 25th contract research organization (CRO) acquisition of 2023.
CRO Kottmann is an international CRO based in Germany. The company conducts clinical studies with medical devices, in vitro diagnostics and pharmaceuticals. In addition to full service, CRO Kottmann also offers individual services such as the creation of databases, statistical evaluations and clinical monitoring for studies.
RQM+ provides regulatory and quality solutions that accelerate the success of medical device companies. The company also provides comprehensive clinical trial, lab and reimbursement services, reducing risk throughout the entire product lifecycle for medical devices, digital therapeutics and diagnostics.
The integration of CRO Kottmann enhances RQM+’s existing geographical footprint in global operations as well as ensures comprehensive end-to-end support for clients, from pre-clinical phases to product commercialization. DLA Piper served as legal advisor and Translink Corporate Finance as M&A advisor to RQM+.
